New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON
> This Story

Forward Printable StoryPrint Comment




Cardiology Homepage

Adagio Medical announces US FDA investigational device exemption approval for atrial fibrillation trial with cryoablation

Philips unveils HeartStart Intrepid with IntelliSpace Connect across Europe and select markets worldwide

FDA expands indication for several transcatheter heart valves

Edwards SAPIEN 3 TAVR receives FDA approval for low-risk patients

The power of 4D technology advances care for heart patients

AtriCure enters into definitive agreement to acquire SentreHEART

Ancora Heart enrolls first patient in European multi-center study of first-of-its-kind investigational heart failure therapy

First TAVR procedure performed at Henry Ford Macomb Hospital

Endologix receives IDE approval for the Nellix Chimney EndoVascular Aneurysm Sealing Protocol

Transport by mobile stroke units get patients quicker treatment than ambulance

New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON

Press releases may be edited for formatting or style
MONROE TOWNSHIP, N.J., July 15, 2019 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, shares the results of a new prospective clinical study of the use of ultrasound enhancing agents (UEAs) in transthoracic echocardiography reaffirming the proven safety profile of its LUMASON ultrasound enhancing agent. The overall incidence of adverse events (AEs) in the study was extremely low and the observed AEs were non-serious. The authors reported the rate of AEs following administration of LUMASON agent to be significantly lower than that after administration of the UEA Definity®. The study is published in the journal Echocardiography.1

UEAs are used in echocardiography to improve image quality and provide real-time assessment of intracardiac blood flow in patients whose conditions, such as large body habitus, lung artifact, increased anterior–posterior diameter, and excessive cardiac motion, may impair image resolution and quality.2

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

"The positive impact of ultrasound enhancing agents is indisputable as they have significantly improved the quality and cost-effectiveness of cardiac clinical care, but these agents are underutilized by the clinical community due to concerns about potential allergic reactions," said study investigator Stephen B. Heitner, MD, Clinical Echocardiography Laboratory, OHSU Hypertrophic Cardiomyopathy Center, Oregon Health & Science University. "Our study shows an extremely low overall incidence of adverse effects events with routine clinical use of ultrasound enhancing agents and confirms that they should be used with all appropriate patients, including those with known intra-cardiac shunts."

Study Design and Results
This was a prospective observational study conducted at Oregon Health & Science University to determine the rate and severity of AEs following UEA administration, assess whether microbubbles are safe when administered to patients with intracardiac shunts, and assess whether the rate and type of AEs differ significantly among LUMASON, Definity and Optison™, the three UEAs approved by the U.S. Food and Drug Administration.

Over a 15-month period, 5,476 echocardiographic studies with UEAs were performed in 5,013 patients. A total of 5,521 UEA administrations were completed: 2,137 with LUMASON, 3,306 with Definity and 78 with Optison. Due to the low number of procedures with Optison, no meaningful comparison between this agent and the other two UEAs could be made.
  Pages: 1 - 2 - 3 - 4 >>

Cardiology Homepage

You Must Be Logged In To Post A Comment